Fig. 1.
Evaluation of cell viability by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. (A) MDA-MB-231 and (B) MCF-7 breast cancer cell lines after 48 hr of melatonin treatment; (C) MDA-MB-231 and (D) MCF-7 breast cancer cell lines after 24 hr of Y27632 treatment. Significant value in ANOVA followed by Bonferroni’s test (±S.E.M. *P < 0.05).